[CLDX] Celldex Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization: 442.27 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 3.76 Change: 0.15 (4.16%)
Ext. hours: Change: 0 (0%)

chart CLDX

Refresh chart

Strongest Trends Summary For CLDX

CLDX is in the medium-term down -55% below S&P in 1 year. In the long-term down -94% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011) is a targeted antibody-drug conjugate in a randomized study for the treatment of triple negative breast cancer. The company also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjug

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding98.72 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -17.91% Sales Growth - Q/Q-67.1% P/E
P/E To EPS Growth P/S120.97 P/BV1.18 Price/Cash Per Share1.23
Price/Free Cash Flow-4.27 ROA-29.03% ROE-31.51% ROI
Current Ratio17.22 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-3334.85% Net Profit Margin-3237.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities191.76 M Cash From Investing Activities-65.03 M Cash From Operating Activities-32.59 M Gross Profit
Net Profit-30.17 M Operating Profit-30.98 M Total Assets407.7 M Total Current Assets364.13 M
Total Current Liabilities21.15 M Total Debt Total Liabilities32.15 M Total Revenue490 K
Technical Data
High 52 week10.36 Low 52 week2.05 Last close2.38 Last change2.15%
RSI67.92 Average true range0.12 Beta1.39 Volume1.44 M
Simple moving average 20 days5.64% Simple moving average 50 days6.33% Simple moving average 200 days-32.96%
Performance Data
Performance Week11.22% Performance Month-3.25% Performance Quart-2.06% Performance Half-41.23%
Performance Year-62.22% Performance Year-to-date-19.82% Volatility daily2.7% Volatility weekly6.05%
Volatility monthly12.39% Volatility yearly42.92% Relative Volume247.49% Average Volume136.7 K
New High New Low


2020-05-28 15:22:58 | Hedge Funds Are Dumping Celldex Therapeutics, Inc. CLDX

2020-05-25 11:30:03 | Is Celldex Therapeutics CLDX Stock Outpacing Its Medical Peers This Year?

2020-05-06 16:01:10 | Celldex Provides Corporate Update and Reports First Quarter 2020 Results

2020-05-06 11:30:03 | Is Celldex Therapeutics, Inc. CLDX Stock Outpacing Its Medical Peers This Year?

2020-05-06 08:01:10 | Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology EAACI Annual Congress 2020

2020-04-24 08:56:12 | Celldex CLDX Soars: Stock Adds 10% in Session

2020-04-14 08:37:12 | Moleculin MBRX Looks Good: Stock Adds 5.3% in Session

2020-04-06 08:53:12 | UroGen URGN Looks Good: Stock Adds 8.1% in Session

2020-03-26 16:01:10 | Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

2020-03-03 08:01:10 | Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program

2019-12-23 10:26:33 | Is Celldex Therapeutics, Inc. CLDX A Good Stock To Buy?

2019-12-12 11:30:04 | Celldex CLDX Down 3.9% Since Last Earnings Report: Can It Rebound?

2019-11-18 08:01:00 | Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

2019-11-14 09:44:02 | Celldex CLDX Q3 Loss Narrower Than Expected, Revenues Miss

2019-11-12 09:25:02 | Celldex Therapeutics CLDX Reports Q3 Loss, Lags Revenue Estimates

2019-11-12 08:01:00 | Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

2019-11-11 08:01:00 | Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

2019-11-08 07:30:00 | CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

2019-10-30 10:33:02 | Will Celldex Therapeutics CLDX Report Negative Q3 Earnings? What You Should Know

2019-10-02 08:01:00 | Celldex Therapeutics Announces Upcoming Data Presentations

2019-09-30 16:01:00 | Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

2019-09-06 09:31:01 | Why Is Celldex CLDX Down 2.3% Since Last Earnings Report?

2019-08-14 09:10:01 | Kadmon KDMN Completes Enrollment in KD025 Study for cGVHD

2019-08-14 00:48:37 | Edited Transcript of CLDX earnings conference call or presentation 7-Aug-19 8:30pm GMT

2019-08-13 11:53:03 | Mallinckrodt Enrolls First Patient in Liver Disease Study

2019-08-13 09:50:01 | Regeneron Ebola Treatment Shows Promise, Study Stopped Early

2019-08-08 16:23:32 | Celldex Therapeutics Inc CLDX Q2 2019 Earnings Call Transcript

2019-08-08 10:54:02 | Celldex CLDX Q2 Loss Narrower Than Expected, Revenues Miss

2019-08-08 06:00:00 | Celldex Therapeutics Keeps Up Its Penny-Pinching and Pipeline Progress

2019-08-07 18:45:10 | Celldex Therapeutics CLDX Reports Q2 Loss, Misses Revenue Estimates

2019-07-31 16:01:00 | Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call

2019-06-24 08:01:00 | Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer

2019-06-06 09:31:01 | Why Is Celldex CLDX Down 29.2% Since Last Earnings Report?

2019-06-04 10:26:02 | Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down

2019-06-04 07:45:58 | The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-tender Offer

2019-06-01 14:15:00 | Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma

2019-05-26 17:03:35 | The Week Ahead In Biotech: ASCO Presentations In The Spotlight

2019-05-14 12:36:35 | Wall Street Sees 3 Falling Knives Rebounding Within 52 Weeks

2019-05-08 07:00:00 | Celldex Therapeutics Continues to Stretch Out Its Cash and Advance Its Pipeline

2019-05-07 18:15:10 | Celldex Therapeutics CLDX Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 17:09:46 | Celldex: 1Q Earnings Snapshot

2019-05-07 16:01:00 | Celldex Provides Corporate Update and Reports First Quarter 2019 Results

2019-05-02 10:32:02 | Celldex Therapeutics CLDX May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-06 09:30:01 | Celldex CLDX Down 5.7% Since Last Earnings Report: Can It Rebound?

2019-04-02 08:00:00 | Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research AACR Annual Meeting 2019

2019-04-01 13:00:00 | Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research AACR Annual Meeting 2019

2019-03-20 09:30:01 | Is Celldex Therapeutics CLDX Stock Outpacing Its Medical Peers This Year?

2019-03-08 11:04:04 | Celldex CLDX Q4 Loss Narrower than Expected, Sales Beat

2019-03-08 07:45:00 | Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling

2019-03-07 20:39:47 | Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT